The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt

被引：56

作者：

Gills, JJ ^{[1
]}

Dennis, PA ^{[1
]}

机构：

[1] NCI, Canc Therapeut Branch, Ctr Canc Res, Navy Med Oncol, Bethesda, MD 20889 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2004年 / 13卷 / 07期

关键词：

Akt; cancer; phosphatidylinositol ether lipid analogue; pleckstrin homology domain;

D O I：

10.1517/13543784.13.7.787

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The serine/threonine kinase Akt is a component of the phosphatidylinositol 3'-kinase/Akt signal transduction pathway that is activated by receptor tyrosine kinases, -activated Ras and integrins. As Akt regulates many processes crucial to carcinogenesis, and Akt activation has been observed in human cancers, intense efforts are underway to develop Akt inhibitors as cancer therapeutics. Towards this aim, phosphatidylinositol ether lipid analogues (PlAs), which are structurally similar to the products of phosphatidylinositol 3'-kinase, have been synthesised. PlAs inhibit Akt translocation, phosphorylation and kinase activity. Furthermore, they selectively induce apoptosis in cancer cell lines that depend on Akt for survival. This review will trace the development of PlAs, cover the biological activities of PlAs and discuss future steps and challenges in their development.

引用

页码：787 / 797

页数：11

共 60 条

[41] D-3-DEOXY-3-SUBSTITUTED MYOINOSITOL ANALOGS AS INHIBITORS OF CELL-GROWTH [J].

POWIS, G ;

AKSOY, IA ;

MELDER, DC ;

AKSOY, S ;

EICHINGER, H ;

FAUQ, AH ;

KOZIKOWSKI, AP .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (02) :95-104

[42] 3-deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth [J].

Qiao, LX ;

Nan, FJ ;

Kunkel, M ;

Gallegos, A ;

Powis, G ;

Kozikowski, AP .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3303-3306

[43] Toward a PKB inhibitor: Modification of a selective PKA inhibitor by rational design [J].

Reuveni, H ;

Livnah, N ;

Geiger, T ;

Kleid, S ;

Ohne, O ;

Cohen, I ;

Benhar, M ;

Gellerman, G ;

Levitzki, A .

BIOCHEMISTRY, 2002, 41 (32) :10304-10314

[44] Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides [J].

Rong, SB ;

Hu, YH ;

Enyedy, I ;

Powis, G ;

Meuillet, EJ ;

Wu, XW ;

Wang, RX ;

Wang, SM ;

Kozikowski, AP .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (06) :898-908

[45] AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis [J].

Roy, HK ;

Olusola, BF ;

Clemens, DL ;

Karolski, WJ ;

Ratashak, A ;

Lynch, HT ;

Smyrk, TC .

CARCINOGENESIS, 2002, 23 (01) :201-205

[46]

Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO

[47]

2-R

[48] Functional roles of Akt signaling in mouse skin tumorigenesis [J].

Segrelles, C ;

Ruiz, S ;

Perez, P ;

Murga, C ;

Santos, M ;

Budunova, IV ;

Martínez, J ;

Larcher, F ;

Slaga, TJ ;

Gutkind, JS ;

Jorcano, JL ;

Paramio, JM .

ONCOGENE, 2002, 21 (01) :53-64

[49] PIK3CA is implicated as an oncogene in ovarian cancer [J].

Shayesteh, L ;

Lu, YL ;

Kuo, WL ;

Baldocchi, R ;

Godfrey, T ;

Collins, C ;

Pinkel, D ;

Powell, B ;

Mills, GB ;

Gray, JW .

NATURE GENETICS, 1999, 21 (01) :99-102

[50] Arsenite activation of PI3K/AKT cell survival pathway is mediated by p38 in cultured human keratinocytes [J].

Souza, K ;

Maddock, DA ;

Zhang, QS ;

Chen, JP ;

Chiu, C ;

Mehta, S ;

Wan, YS .

MOLECULAR MEDICINE, 2001, 7 (11) :767-772

← 1 2 3 4 5 6 →